 made the announcement on Wednesday that Nigeria has begun using their rotavirus oral vaccination ROTAVAC to protect their children against the potentially fatal diarrheal sickness that affects millions of children throughout the globe.){kind=link}
Bharat Biotech International Limited (BBIL) made the announcement on Wednesday that Nigeria has begun using their rotavirus oral vaccination ROTAVAC to protect their children against the potentially fatal diarrheal sickness that affects millions of children throughout the globe.
At this time, Nigeria is responsible for 14 percent of all children rotavirus fatalities that occur throughout the globe. As a result, Nigeria is the nation with the second-highest number of rotavirus deaths of any country in the world. The rotavirus is responsible for the deaths of around 50,000 children in Nigeria who are under the age of five every year.
“The ROTAVAC is the culmination of decades of study and product development,” the company says. Several nations in Asia, Africa, Latin America, and the Middle East now stock this vaccine, making it more accessible to more people. We are elated to announce that innovative Indian vaccinations are helping to save lives all around the globe. In addition, we are committed to reducing the number of children who die from infectious diseases each year. Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech, stated in a release that ROTAVAC® is both safe and effective in preventing diarrheal sickness caused by the Rotavirus.
Ella also noted that Bharat Biotech would continue to play its role in the research, development, and production of innovative vaccines, with the goals of reducing the morbidity and mortality caused by infectious illnesses and contributing towards the realisation of universal access to vaccinations.
Over forty percent of all cases of diarrhoea in children are caused by rotavirus, making it one of the most common infectious agents that may contribute to this condition. Because it is the most prevalent cause of severe diarrhoea, it is responsible for about 215,000 of the 525,000 deaths of children under the age of 5 that are ascribed to diarrheal infections each year across the globe.
The World Health Organization (WHO) granted ROTAVAC prequalification status in January of 2018. According to the company, Bharat Biotech developed the first generation rotavirus vaccine known as Rotavac through a Public-Private Partnership with the Department of Biotechnology, the Government of India, and 16 other international partners. This would make it the largest social innovation project ever undertaken for the purpose of improving public health.